To include your compound in the COVID-19 Resource Center, submit it here.

Benjorna: Phase III data

The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE